Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verpacamide a
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
01
Overview
Verpacamide A is an experimental small molecule classified as an alpha amino acid derivative, specifically a cyclic dipeptide composed of L-arginine and L-proline. Its chemical formula is C11H19N5O2, and it has been referenced as "cyclo-(L-arginine-L-proline) inhibitor." There are no approved indications or clinical trials reported for this compound. The mechanism of action and therapeutic applications remain uncharacterized in the available literature[1][2][3].
- Other names
- cyclo-(l-arginine-l-proline) inhibitor
Beyond the preview
Go deeper on verpacamide a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verpacamide a.